ArticleFrontiers in pharmacology2026
Sophoridine attenuates osteoarthritis progression: association with suppression of chondrocyte pyroptosis via inhibiting NF-κB signaling pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a degenerative musculoskeletal disease characterized by cartilage degradation and inflammation. Sophoridine (SR), a quinolizidine alkaloid from traditional Chinese herbs, has demonstrated anti-inflammatory properties, but its role in OA is unknown. Methods: The effects of SR on chondrocyte viability were assessed using the Cell Counting Kit-8 (CCK-8) assay. Interleukin-1β (IL-1β)-stimulated murine primary chondrocytes were used as an Results: In IL-1β-stimulated chondrocytes, SR (20 and 40 μg/mL) significantly inhibited ECM degradation and suppressed the expression of pro-inflammatory cytokines. Conclusion: Our study indicates that SR effectively attenuates OA progression, which was associated with the suppression of chondrocyte pyroptosis and inflammation via NF-κB signaling pathway inhibition, suggesting SR as a promising therapeutic agent for OA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.